What is ARTBIO?
ARTBIO is at the forefront of developing a new class of alpha radioligand therapies (ART) aimed at transforming cancer treatment. Headquartered in Cambridge, Massachusetts, the company is not only creating these advanced therapies but also building the necessary ecosystem to maximize their clinical and commercial potential. Their approach targets the development of innovative treatments for various cancers, positioning them as a key player in the evolving landscape of oncology.
How much funding has ARTBIO raised?
ARTBIO has raised a total of $245M across 3 funding rounds:
Angel/Seed
$23M
Series A
$90M
Series B
$132M
Angel/Seed (2023): $23M with participation from F-Prime Capital Partners
Series A (2023): $90M led by F-Prime Capital Partners, Omega Fund Management, and Third Rock Ventures
Series B (2025): $132M supported by Omega Fund Management, Qatar Investment Authority, B Capital Group, F-Prime Capital, Alexandria, Third Rock Ventures, and Sofinnova Partners
Key Investors in ARTBIO
F-Prime Capital Partners
F-Prime Capital Partners is a venture capital firm based in Massachusetts, investing in healthcare and technology companies with a team of investors, engineers, doctors, and scientists.
Omega Fund Management
Omega Funds is a venture capital firm focused on investing in exceptional founders and entrepreneurs in therapeutic areas like oncology and immunology, aiming to bring science to patients.
Third Rock Ventures
Third Rock Ventures is a healthcare venture firm dedicated to discovering, launching, and building companies that make a significant difference in people's lives through disruptive science and medicine.
What's next for ARTBIO?
With substantial backing, ARTBIO is poised for accelerated growth and the scaling of its therapeutic pipeline. The significant enterprise-level funding suggests a strategic focus on clinical development, regulatory approvals, and market penetration. Future endeavors will likely involve expanding their research and development capabilities, forging strategic partnerships, and advancing their ART therapies through late-stage clinical trials, ultimately aiming to bring these potentially life-saving treatments to patients.
See full ARTBIO company page
